No Data
No Data
Bicycle Therapeutics (NASDAQ:BCYC) Shareholders Have Endured a 74% Loss From Investing in the Stock Three Years Ago
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
European Equities Traded in the US as American Depositary Receipts Rise Thursday
Optimistic Outlook on Bicycle Therapeutics Amid Mixed Clinical Results and Strategic Roadmap
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $26 to $40
Express News | Bicycle Therapeutics PLC : Leerink Partners Cuts Target Price to $26 From $28